Whippany, N.J., June 5, 2026
Summary
Bayer announced today full results from the Phase III FIND-CKD trial investigating KERENDIA® (finerenone) in adults with non-diabetic chronic kidney disease (nd-CKD) who were also receiving background standard of care. In the trial, KERENDIA met the primary endpoint by showing a significant reduction in the rate of kidney disease progression, as measured by estimated glomerular filtration rate (eGFR) slope (mean annual change from baseline to month 32), compared with placebo.1 KERENDIA also showed a statistically significant reduction in the risk of a secondary composite kidney-cardiovascular endpoint, which included kidney failure, sustained eGFR decrease ≥57%, hospitalization for heart failure, or cardiovascular death, versus placebo.1
These results were presented as a late breaker at the 63rd European Renal Association (ERA) Congress on June 5th, 2026, in Glasgow, Scotland, and were simultaneously published in the New England Journal of Medicine.